Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Weight Loss 1Cachexia 1Advanced Cancer 1

Interventions

Cyclophosphamide 3155Cisplatin 3151Carboplatin 2929Paclitaxel 2671Radiotherapy 2643Gemcitabine 2544pembrolizumab 2324Docetaxel 2154Bevacizumab 2126Fluorouracil 1819Capecitabine 1780Oxaliplatin 1709Dexamethasone 1589Nivolumab 1516Doxorubicin 1477Rituximab 1453Etoposide 1341Magnetic Resonance Spectroscopy 1261Irinotecan 1232Leucovorin 1212Cytarabine 1123Pemetrexed 1060Drug Therapy 1060fludarabine 1044Vincristine 956Specimen Handling 928Prednisone 924Cetuximab 919Lenalidomide 916Trastuzumab 897

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × olanzapine-fluoxetine combination × Clear all
NCT00489593 2015-01-08

Olanzapine in Patients With Advanced Cancer and Weight Loss

M.D. Anderson Cancer Center

Phase 1 Completed
57 enrolled

Cachexia, Weight Loss

NCT00512291 2011-09-27

Subcutaneous Olanzapine for Hyperactive or Mixed Delirium

M.D. Anderson Cancer Center

Phase NA Completed
25 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡